Novartis faces securities fraud probe after drug trial failure causes stock to drop 14%.

Pomerantz LLP is investigating Novartis and some of its executives for possible securities fraud following the company's announcement that its Phase III trial for del-desiran in myotonic dystrophy type 1 patients failed to show significant improvement. This news led to a nearly 14% drop in Novartis's American Depositary Share price on September 8, 2026. The investigation could impact investor confidence and lead to legal actions if wrongdoing is found. Investors affected are encouraged to contact Pomerantz LLP for more information.

As of Oct 01, 2026 21:12 WIB, Novartis AG (NVS) shares trade at USD 142.21 on Pluang, showing a modest 0.25% decline in the last day. The stock's market capitalization stands at $273.29 billion with a dividend yield of 3.32%. Notably, Pluang order activity is currently 100% sell, reflecting cautious sentiment among investors following recent developments.